Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. MATERIALS AND METHODS: Eligible patients had platinum-resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamanishi, Junzo, Takeshima, Nobuhiro, Katsumata, Noriyuki, Ushijima, Kimio, Kimura, Tadashi, Takeuchi, Satoshi, Matsumoto, Koji, Ito, Kimihiko, Mandai, Masaki, Nakai, Hidekatsu, Sakuragi, Noriaki, Watari, Hidemichi, Takahashi, Nobutaka, Kato, Hidenori, Hasegawa, Kosei, Yonemori, Kan, Mizuno, Mika, Takehara, Kazuhiro, Niikura, Hitoshi, Sawasaki, Takashi, Nakao, Sari, Saito, Toshiaki, Enomoto, Takayuki, Nagase, Satoru, Suzuki, Nao, Matsumoto, Takashi, Kondo, Eiji, Sonoda, Kenzo, Aihara, Satomi, Aoki, Yoichi, Okamoto, Aikou, Takano, Hirokuni, Kobayashi, Hiroshi, Kato, Hisamori, Terai, Yoshito, Takazawa, Akira, Takahashi, Yusuke, Namba, Yoshinobu, Aoki, Daisuke, Fujiwara, Keiichi, Sugiyama, Toru, Konishi, Ikuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601279/
https://www.ncbi.nlm.nih.gov/pubmed/34473544
http://dx.doi.org/10.1200/JCO.21.00334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601279/
https://www.ncbi.nlm.nih.gov/pubmed/34473544
http://dx.doi.org/10.1200/JCO.21.00334

Ejemplares similares